Proline-Methotrexate

What is Proline-Methotrexate

**Introduction to Proline-Methotrexate** Proline-Methotrexate is a specialized formulation of methotrexate, a well-established antifolate and immunosuppressive agent. This modified version incorporates a proline moiety to enhance stability, bioavailability, or targeted delivery, potentially improving therapeutic efficacy while minimizing side effects. Methotrexate is widely used in oncology for treating cancers such as leukemia and lymphoma, as well as in autoimmune conditions like rheumatoid arthritis and psoriasis. Proline-Methotrexate may offer advantages such as reduced toxicity or improved pharmacokinetics, making it a promising option for patients requiring long-term treatment. Further research and clinical studies are ongoing to validate its benefits and optimize dosing regimens for broader medical use. (100 words)

Preparation Process: To prepare Proline-Methotrexate, follow these steps: 1. **Activation of Proline**: Dissolve L-proline in anhydrous DMF, then add HOBt and EDC·HCl at 0°C to activate the carboxyl group. Stir for 30 min under nitrogen. 2. **Coupling with Methotrexate**: Add methotrexate (MTX) to the activated proline solution, adjusting pH to 8–9 with NMM. React at room temperature for 12–24 h. 3. **Purification**: Quench the reaction with water, extract with ethyl acetate, and wash with brine. Dry over Na₂SO₄, concentrate, and purify by silica gel chromatography (CH₂Cl₂/MeOH). 4. **Characterization**: Confirm the product (Proline-MTX conjugate) via HPLC, MS, and NMR.

Usage Scenarios: Proline-Methotrexate is a modified form of methotrexate (MTX), where proline is conjugated to enhance drug delivery and therapeutic efficacy. This compound is primarily investigated for its potential in targeted cancer therapy, leveraging proline's role in improving cellular uptake and tumor specificity. It retains MTX's ability to inhibit dihydrofolate reductase (DHFR), disrupting folate metabolism and DNA synthesis in rapidly dividing cells. Proline-Methotrexate may offer reduced systemic toxicity and improved pharmacokinetics compared to conventional MTX, making it a candidate for treating malignancies, autoimmune diseases, and inflammatory conditions. Research focuses on optimizing its selectivity and minimizing off-target effects.

Proline-Methotrexate Basic Info

Proline-Methotrexate Price